Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 5.97% is 29% below its 1-year average of 8.43%, near the low end of its 1-year range (5.97%–10.78%).
As of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 5.97%.
RETURN ON EQUITY (ROE)
5.97%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-54.10%
vs the sector median at left
Market Cap
$26.93B
Return on Equity (ROE)
14.13%
TTM Avg
13.34%
3Y Avg
14.07%
5Y Avg
18.07%
Market Cap
$26.37B
Return on Equity (ROE)
7062.40%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
Market Cap
$26.08B
Return on Equity (ROE)
11.65%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$28.96B
Return on Equity (ROE)
14.51%
TTM Avg
21.84%
3Y Avg
21.53%
5Y Avg
32.27%
Market Cap
$25.23B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$24.40B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$24.15B
Return on Equity (ROE)
-9.62%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$30.66B
Return on Equity (ROE)
83.10%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medline Inc. (MDLN) | $27.38B | 5.97% | N/A | N/A | N/A |
| Quest Diagnostics Incorporated (DGX)vs › | $26.93B | 14.13% | 13.34% | 14.07% | 18.07% |
| Mettler-Toledo International Inc. (MTD)vs › | $26.37B | 7062.40% | -2178.82% | -341.14% | -117.12% |
| Labcorp Holdings Inc. (LH)vs › | $26.08B | 11.65% | 9.71% | 9.35% | 12.84% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $28.96B | 14.51% | 21.84% | 21.53% | 32.27% |
| West Pharmaceutical Services, Inc. (WST)vs › | $25.23B | 18.89% | 16.95% | 19.08% | 20.56% |
| Incyte Corporation (INCY)vs › | $24.40B | 25.41% | 12.92% | 11.29% | 9.83% |
| BioNTech SE (BNTX)vs › | $24.15B | -9.62% | -4.55% | 10.63% | 21.70% |
| Zoetis Inc. (ZTS)vs › | $30.66B | 83.10% | 66.19% | 56.82% | 52.60% |
| Waters Corporation (WAT)vs › | $31.17B | 1.09% | 29.98% | 64.02% | 111.55% |
ROE
6.0%
ROA
1.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 5.97% |
| 2026-03-31 | 8.55% |
| 2025-12-31 | 10.78% |
